AbbVie Immunology is a large pharma headquartered in US. Over the past three years, AbbVie Immunology has been involved in 23 licensing and acquisition transactions, with a primary focus on Other (14 deals). The company currently has 50 active clinical trials, primarily in Codev Deals.
Deals (12mo)
8
Active Trials
50
Top Modality
Other
Focus Area
Codev Deals
Licensing, acquisition, and partnership transactions involving AbbVie Immunology in the past 12 months.
| Asset |
|---|
| Partner |
|---|
| Modality |
|---|
| Phase |
|---|
| Type |
|---|
| Date |
|---|
| Imbruvica | Janssen | Small Molecules | Approved | co development | Jul 17, 2026 |
| age-related diseases program | AbbVie | Other | Unknown | co development | Jul 5, 2026 |
| age-related diseases platform | AbbVie | Other | Unknown | co development | Jul 3, 2026 |
| RC148 | AbbVie | ADC | Unknown | license | Jul 1, 2026 |
| VivoVec CAR-T candidates | AbbVie | CAR-T | Unknown | option | Jun 27, 2026 |
| Apogee Therapeutics portfolio (Dupixent competitor / long-acting autoimmune biologics) | AbbVie | Antibodies | Phase 3 | acquisition | Jun 22, 2026 |
| APG777 | AbbVie | Antibodies | Preclinical | acquisition | Jun 15, 2026 |
| BI 655066 | AbbVie | Other | Phase 3 | license | Mar 23, 2026 |
| BI 655064 | AbbVie | Other | Phase 1 | license | Mar 23, 2026 |
Therapeutic areas and modalities where AbbVie Immunology is most active based on deal history and clinical trial data.
Key indicators of AbbVie Immunology's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Acquisition Appetite
Strategic Priorities
AbbVie Immunology has 50 active clinical trials across 6 development phases.
9
Unknown
2
Phase 4
1
Not Applicable
24
Phase 1
12
Phase 2
2
Phase 3
Use Solidus to benchmark upfront payments, milestones, and royalties for Codev Deals assets — powered by data from 3,500+ real biopharma transactions.
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
AbbVie Immunology is a large pharma company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 23 deals over the past three years, AbbVie Immunology ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for AbbVie Immunology include Codev Deals (8 deals and trials), Hematological Malignancies (7 deals and trials), Oncology (6 deals and trials), and Dermatology (6 deals and trials). In terms of modality, AbbVie Immunology has shown particular interest in other, small molecules, antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for AbbVie Immunology and 850+ other biopharma companies. Use our Solidus to benchmark your asset against AbbVie Immunology's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.
© 2026 Ambrosia Ventures. All rights reserved.
Benchmarks powered by 1,600+ real biopharma licensing deals